AstraZeneca's liver cancer therapy combo slows disease progression in late-stage trial
Published on April 2, 2026.
AstraZeneca (AZN.L) has announced that a combination treatment with its cancer drug Imfinzi, which slows disease progression in a late-stage trial, has shown significant improvement in how long patients with a common liver cancer live before their disease worsened. This is compared to when patients only underwent a procedure called transarterial chemoembolisation (TACE) for unresectable hepatocellular carcinoma. The drugmaker also noted that Imfinz was given in combination with other cancer treatments Imjudo and lenvatinib, along with a standard cancer-targeting procedure for early-stage liver cancer. Analysts at JP Morgan predict peak annual sales of $11.3 billion for the Imfiniz combination, which is above current market expectations of about $10.6 billion.
Related Articles
Kabukicho psychiatrist accused of raping female patient has long history of abusing women - TokyoReporter
Tokyo psychiatrist Jun Izawa, arrested for sexually assaulting a patient, has a history of domestic violence and drug abuse, leading to his arrest.
Tesla's first-quarter deliveries miss estimates as tax credit expiry weighs
Tesla's first-quarter deliveries missed estimates, with the expiry of a $7,500 tax credit impacting EV demand, while China-made vehicles rose.
Four businesses red-tagged in city’s latest inspection report
Albuquerque Environmental Health inspectors highlighted numerous violations at four restaurants, including inadequate sanitizer, inadequate cold-holding equipment, improper storage, and unsafe temperatures.